Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Urogynecology Journal
Published in: International Urogynecology Journal 8/2018

01-08-2018 | Review Article

Role of sacral neuromodulation in modern urogynaecology practice: a review of recent literature

Author: Samina Tahseen

Published in: International Urogynecology Journal | Issue 8/2018

Login to get access

Abstract

Sacral neuromodulation (SNM) offers promise in the therapy of many pelvic floor disorders. This innovative treatment has slowly gained popularity. A review of recent literature is presented in relation to its efficacy and complications in various pelvic floor conditions: overactive bladder and urge urinary incontinence, chronic urinary retention, painful bladder syndrome, pelvic pain and double incontinence. It is a minimally invasive, completely reversible safe procedure with good long-term outcomes. However, the treatment is costly, the revision rate is high and patients require life-long follow-up. SNM should always be considered in suitable patients before offering bladder augmentation procedures or urinary diversion or permanent catheterization for bladder dysfunction. SNM should also be considered in patients with double incontinence, after discussion in a urogynaecology/colorectal multidisciplinary team.
Literature
1.
Gormley EA, Lightner DJ, Faraday M, Vasavada SP (2015) Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urology 193:1572–1580CrossRef
2.
Tse V, King J, Dowling C, English S et al (2016) Conjoint Urological Society of Australia and New Zealand (USANZ) and Urogynaecological Society of Australasia (UGSA) Guidelines on the management of adult non-neurogenic overactive bladder. BJU Int 117:34–47CrossRefPubMed
3.
4.
5.
6.
7.
Tanagho EA, Schmidt RA (1986) Controlled voiding with neurostimulation. J Urol 135(Suppl):262A, abstract 635. Proceedings of the American Urological Association 81st Annual Meeting, 18–22 May 1986, New York
8.
Spinelli M, Giardiello G, Gerber M, Arduini A, van den Hombergh U, Malaguti S (2003) New sacral neuromodulation lead for percutaneous implantation using local anesthesia: description and first experience. J Urol 170:1905–1907CrossRefPubMed
9.
Tanagho EA, Schmidt RA (1982) Bladder pacemaker: scientific basis and clinical future. Urology 20:614–619CrossRefPubMed
10.
Fall M, Lindstrom S (1991) Electrical stimulation. A physiologic approach to the treatment of urinary incontinence. Urol Clin North Am 18:393–407PubMed
11.
Schultz-Lampel D, Jiang C, Lindström S, Thüroff JW (1998) Experimental results on mechanisms of action of electrical neuromodulation in chronic urinary retention. World J Urol 16:301–304CrossRefPubMed
12.
Blok BF, Groen J, Bosch JL, Veltman DJ, Lammertsma AA (2006) Different brain effects during chronic and acute sacral neuromodulation in urge incontinent patients with implanted neurostimulators. BJU Int 98:1238–1243CrossRefPubMed
13.
14.
Abrams P, Andersson KE, Birder L et al (2010) Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn 29:213–240CrossRefPubMed
15.
Abrams P, Khoury S, Wein AJ (1999) Incontinence: First International Consultation on Incontinence. World Health Organization. Health Publications: Plymouth, UK
16.
Basra RK, Wagg A, Chapple C et al (2008) A review of adherence to drug therapy in patients with overactive bladder. BJU Int 102:774–779CrossRefPubMed
17.
Mohee A, Khan A, Harris N et al (2013) Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB). BJU Int 111:106–113CrossRefPubMed
18.
Weil EH, Eerdmans PH, Janknegt R (1996) A new randomized study of neuromodulation versus conventional treatment for incontinence or dysfunctional voiding patterns a preliminary report. Neurourol Urodyn 15(4):284–285
19.
Schmidt RA, Jonas U, Oleson KA et al (1999) Sacral nerve stimulation for treatment of refractory urinary urge incontinence: sacral nerve stimulation study group. J Urol 162:352–357CrossRefPubMed
20.
Weil EH, Ruiz-Cerda JL, Eerdmans PH, Janknegt RA, Bemelmans BL, van Kerrebroeck PE (2000) Sacral root neuromodulation in the treatment of refractory urinary urge incontinence: a prospective randomized clinical trial. Eur Urol 37:161–171CrossRefPubMed
21.
Everaert K, Kerckhaert W, Caluwaerts H (2002) The staged implant does not increase subjective or objective improvement in overactive bladder symptoms in patients selected for sacral nerve stimulation. Neurourol Urodyn 21:402CrossRef
22.
Herbison GP, Arnold EP (2009) Sacral neuromodulation with implanted devices for urinary storage and voiding dysfunction in adults. Cochrane Database Syst Rev CD004202
23.
Brazzelli M, Murray A, Fraser C (2006) Efficacy and safety of sacral nerve stimulation for urinary urge incontinence: a systematic review. J Urol 175:835–841CrossRefPubMed
24.
Siddiqui NY, Wu JM, Amundsen CL (2010) Efficacy and adverse events of sacral nerve stimulation for overactive bladder: a systematic review. Neurourol Urodyn 29(Suppl 1):S18–S23CrossRefPubMed
25.
van Kerrebroeck PE, van Voskuilen AC, Heesakkers JP et al (2007) Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. J Urol 178(5):2029–2034CrossRefPubMed
26.
Moon KH, Han JY, Kim JH, Lee HN (2014) Prospective trial of sacral neuromodulation for refractory overactive bladder syndrome in Korean patients. Low Urin Tract Symptoms 6:175–179CrossRefPubMed
27.
Peeters K, Sahai A, De Ridder D, Van Der Aa F (2014) Long-term follow-up of sacral neuromodulation for lower urinary tract dysfunction. BJU Int 113:789–794CrossRefPubMed
28.
Noblett K, Siegel S, Mangel J, Griebling TL (2016) Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder. Neurourol Urodyn 35:246–251CrossRefPubMed
29.
Groenendijk PM, Lycklama à Nyeholt AA, Heesakkers JP et al (2008) Urodynamic evaluation of sacral neuromodulation for urge urinary incontinence. BJU Int 101:325–329CrossRefPubMed
30.
Siegel S, Noblett K, Mangel J et al (2015) Results of a prospective, randomized, multicentre study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder. Neurourol Urodyn 34:224–230CrossRefPubMed
31.
Leong RK, Marcelisson TA, Nieman FH, de Bie RA, van Kerrebroeck PE, de Wachter SG (2011) Satisfaction and patient experience with sacral neuromodulation: results of a single center sample survey. J Urol 185:588–592CrossRefPubMed
32.
Amundsen CL, Richter HE, Menefee SA et al (2016) OnabotulinumtoxinA vs sacral neuromodulation on refractory urgency urinary incontinence in women: a randomized clinical trial. JAMA 316(13):1366–1374CrossRefPubMedPubMedCentral
33.
Richter HE, Amundsen CL, Erickson SW et al (2017) Characteristics associated with treatment response and satisfaction in women undergoing OnabotulinumtoxinA and sacral neuromodulation for refractory urgency urinary incontinence. J Urol 198:890–896CrossRefPubMedPubMedCentral
34.
Haylen BT, Freeman RM, de Ridder D et al (2010) An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn 29:4–20PubMed
35.
Fowler CJ, Christmas TJ, Chapple CR et al (1988) Abnormal electromyographic activity of the urethral sphincter, voiding dysfunction, and polycystic ovaries: a new syndrome? BMJ 297:1436–1438CrossRefPubMedPubMedCentral
36.
Groutz A, Gordon D, Lessing JB et al (1999) Prevalence and characteristics of voiding difficulties in women: are subjective symptoms substantiated by objective urodynamic data? Urology 54:268–272CrossRefPubMed
37.
Gross C, Habli M, Lindsell C et al (2010) Sacral neuromodulation for nonobstructive urinary retention: a meta-analysis. Female Pelvic Med Reconstr Surg 16:249–253CrossRefPubMed
38.
Jonas U, Fowler CJ, Chancellor MB et al (2001) Efficacy of sacral nerve stimulation for urinary retention: results 18 months after implantation. J Urol 165:15–19CrossRefPubMed
39.
White WM, Dobmeyer-Dittrich C, Klein FA et al (2008) Sacral nerve stimulation for treatment of refractory urinary retention: long-term efficacy and durability. Urology 71:71–74CrossRefPubMed
40.
Denzinger S, Nowrotek A, Weingart P, Burger M et al (2012) Does sacral neuromodulation lead to relevant reduction in the need for intermittent catheterization? A single-center experience on patients with chronic urinary retention. Neuromodulation 15:586–591CrossRefPubMed
41.
Dasgupta R, Wiseman OJ, Kitchen N, Fowler CJ (2004) Long-term results of sacral neuromodulation for women with urinary retention. BJU Int 94:335–337CrossRefPubMed
42.
Aboseif S, Tamaddon K, Chalfin S, Freeman S et al (2002) Sacral neuromodulation in functional urinary retention: an effective way to restore voiding. BJU Int 90:662–665CrossRefPubMed
43.
Mundy AR (1982) An anatomical explanation for bladder dysfunction following rectal and uterine surgery. Br J Urol 54:501–504CrossRefPubMed
44.
Everaert K, De Muynck M, Rimbaut S, Weyers S (2003) Urinary retention after hysterectomy for benign disease: extended diagnostic evaluation and treatment. BJU Int 91:497–501CrossRefPubMed
45.
Everaert K, Kerckhaert W, Caluwaerts H et al (2004) A prospective randomized trial comparing the 1-stage with the 2-stage implantation of a pulse generator in patients with pelvic floor dysfunction selected for sacral nerve stimulation. Eur Urol 45:649–654CrossRefPubMed
46.
Goh M, Diokno AC (2007) Sacral neuromodulation for nonobstructive urinary retention – is success predictable? J Urol 178:197–199CrossRefPubMed
47.
48.
Utomo E, Groen J, Blok BF (2014) Surgical management of functional bladder outlet obstruction in adults with neurogenic bladder dysfunction. Cochrane Database Syst Rev CD004927
49.
Chodez M, Trilling BC, Thuillier C, Boillot B et al (2014) Results of sacral nerve neuromodulation for double incontinence in adults. Tech Coloproctol 18:1147–1151CrossRefPubMed
50.
Faucheron JC, Chodez M, Boillot B (2012) Neuromodulation for fecal and urinary incontinence: functional results in 57 consecutive patients from a single institution. Dis Colon Rectum 55:1278–1283CrossRefPubMed
51.
Tanagho EA, Schmidt RA (1988) Electrical stimulation in the clinical management of the neurogenic bladder. J Urol 140:1331–1339CrossRefPubMed
52.
Bosch R, Groen J (1996) Treatment of refractory urge urinary incontinence with sacral spinal nerve stimulation in multiple sclerosis patients. Lancet 348:717–719CrossRef
53.
Kessler TM, La Framboise D, Trelle S et al (2010) Sacral neuromodulation for neurogenic lower urinary tract dysfunction: systematic review and meta-analysis. Eur Urol 58:865–874CrossRefPubMed
54.
Peters KM, Kandagatla P, Killinger KA et al (2013) Clinical outcomes of sacral neuromodulation in patients with neurologic conditions. Urology 81:738–743CrossRefPubMed
55.
Chaabane W, Guillotreau J, Castel-Lacanal E et al (2011) Sacral neuromodulation for treating neurogenic bladder dysfunction: clinical and urodynamic study. Neurourol Urodyn 30:547–550CrossRefPubMed
56.
Wöllner J, Krebs J, Pannek J (2016) Sacral neuromodulation in patients with neurogenic lower urinary tract dysfunction. Spinal Cord 54:137–140CrossRefPubMed
57.
Engeler DS, Meyer D, Abt D et al (2015) Sacral neuromodulation for the treatment of neurogenic lower urinary tract dysfunction caused by multiple sclerosis: a single centre prospective series. BMC Urol 15:105
58.
Lombardi G, Del Popolo G (2009) Clinical outcome of sacral neuromodulation in incomplete spinal cord injured patients suffering from neurogenic lower urinary tract symptoms. Spinal Cord 47:486–491CrossRefPubMed
59.
Lombardi G, Musco S, Celso M et al (2014) Sacral neuromodulation for neurogenic non-obstructive urinary retention in incomplete spinal cord patients: a ten year follow up single centre experience. Spinal Cord 52:241–245CrossRefPubMed
60.
Drake MJ, Apostolidis A, Cocci A et al (2016) Neurogenic lower urinary tract dysfunction: clinical management recommendations of the Neurologic Incontinence Committee of the Fifth International Consultation on Incontinence 2013. Neurourol Urodyn 35:657–665CrossRefPubMed
61.
van de Merwe JP, Nordling J, Bouchelouche P et al (2008) Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur Urol 53(1):60–67CrossRefPubMed
62.
Hanno P, Lin A, Nordling J, Nyberg L, van Ophoven A, Ueda T et al (2010) Bladder Pain Syndrome Committee of the International Consultation on Incontinence. Neurourol Urodyn 29(1):191–198CrossRefPubMed
63.
Leiby BE, Landis JR, Propert KJ, Tomaszewski JE, Interstitial Cystitis Data Base Study Group (2007) Discovery of morphological subgroups that correlate with severity of symptoms in interstitial cystitis: a proposed biopsy classification system. J Urol 177:142–148CrossRefPubMed
64.
65.
Ito T, Ueda T, Honma Y, Takei M (2007) Recent trends in patient characteristics and therapeutic choices for interstitial cystitis: analysis of 282 Japanese patients. Int J Urol 14:1068–1070CrossRefPubMed
66.
67.
Ghazwani YQ, Elkelini MS, Hassouna MM (2011) Efficacy of sacral neuromodulation in treatment of bladder pain syndrome: long-term follow up. Neurourol Urodyn 30(7):1271–1275PubMed
68.
Gajewski JB, Al-Zahrani AA (2011) The long-term efficacy of sacral neuromodulation in the management of intractable cases of bladder pain syndrome: 14 years of experience in one centre. BJU Int 107:1258–1264CrossRefPubMed
69.
Marinkovic SP, Gillen LM, Marinkovic CM (2011) Minimum 6-year outcomes for interstitial cystitis treated with sacral neuromodulation. Int Urogynecol J 22:407–412CrossRefPubMed
70.
Peter KM, Carey JM, Konstandt DB (2003) Sacral neuromodulation for the treatment of refractory interstitial cystitis: outcomes based on technique. Int Urogynecol J Pelvic Floor Dysfunct 14:223–228CrossRef
71.
Powell CR, Kreder KJ (2010) Long-term outcomes of urgency-frequency syndrome due to painful bladder syndrome treated with sacral neuromodulation and analysis of failures. J Urol 183:173–176CrossRefPubMed
72.
Comiter CV (2003) Sacral neuromodulation for the symptomatic treatment of refractory interstitial cystitis: a prospective study. J Urol 169:1369–1373CrossRefPubMed
73.
Tirlapur S, Vlismas A, Ball E, Khan KS (2013) Nerve stimulation for chronic pelvic pain and bladder pain syndrome: a systematic review. Acta Obstet Gynecol Scand 92:881–887CrossRefPubMed
74.
Latthe P, Latthe M, Say L, Gulmezoglu M, Khan KS (2006) WHO systematic review of prevalence of chronic pelvic pain: a neglected reproductive health morbidity. BMC Public Health 6:177CrossRefPubMedPubMedCentral
75.
76.
Feler CA, Whitworth LA, Fernandez J (2003) Sacral neuromodulation for chronic pain conditions. Anesthesiol Clin North Am 21:785–795CrossRef
77.
Zabihi N, Mourtzinos A, Maher MG, Raz S, Rodriguez LV (2008) The effects of bilateral caudal epidural S2-4 neuromodulation on female sexual function. Int Urogynecol J Pelvic Floor Dysfunct 19:697–700CrossRefPubMed
78.
Martellucci J, Naldini G, Del Popolo G, Carriero A (2012) Sacral nerve modulation in the treatment of chronic pain after pelvic surgery. Colorectal Dis 14(4):502–507CrossRefPubMed
79.
Martellucci J, Naldini G, Carriero A (2012) Sacral nerve modulation in the treatment of chronic pelvic pain. Int J Colorectal Dis 27:921–926CrossRefPubMed
80.
Gill BC, Swartz MA, Firoozi F, Rackley RR et al (2011) Improved sexual and urinary function in women with sacral nerve stimulation. Neuromodulation 14:436–443CrossRefPubMed
81.
Parnell BA, Howard JF Jr, Geller EJ (2015) The effect of sacral neuromodulation on pudendal nerve function and female sexual function. Neurourol Urodyn 34:456–460CrossRefPubMed
82.
Pauls RN, Marinkovic SP, Silva WA, Rooney CM et al (2007) Effects of sacral neuromodulation on female sexual function. Int Urogynecol J Pelvic Floor Dysfunct 18:391–395CrossRefPubMed
83.
Jadav AM, Wadhawan H, Jones GL, Wheldon LW et al (2013) Does sacral nerve stimulation improve global pelvic function in women? Colorectal Dis 15:848–857CrossRefPubMed
84.
Lombardi G, Mondaini N, Macchiarella A, Cilotti A, Del Popolo G (2008) Clinical female sexual outcome after sacral neuromodulation implant for lower urinary tract symptoms (LUTS). J Sex Med 5:1411–1417CrossRefPubMed
85.
86.
Meschia M, Buonaguidi A, Pifarotti P, Somigliana E, Spennacchio M, Amicarelli F (2002) Prevalence of anal incontinence in women with symptoms of urinary incontinence and genital prolapse. Obstet Gynecol 100:719–723PubMed
87.
Soligo M, Salvatore S, Milani R et al (2003) Double incontinence in urogynecologic practice: a new insight. Am J Obstet Gynecol 189:438–443CrossRefPubMed
88.
Matzel KE, Stadelmaier U, Hohenfellner M, Gall FP (1995) Electrical stimulation of sacral spinal nerves for treatment of faecal incontinence. Lancet 346:1124–1127CrossRefPubMed
89.
Leroi AM, Damon H, Faucheron JL et al (2009) Sacral nerve stimulation in faecal incontinence: position statement based on a collective experience. Colorectal Dis 11:572–583
90.
91.
Fraser C, Glazener C, Grant A et al (2004) Systematic review of the efficacy and safety of sacral nerve stimulation for faecal incontinence. Health Services Research Unit, University of Aberdeen, UK
92.
Falletto E, Ganio E, Naldini G, Ratto C, Altomare DF (2014) Sacral neuromodulation for bowel dysfunction: a consensus statement from the Italian group. Tech Coloproctol 18:53–64CrossRefPubMed
93.
Chughtai B, Sedrakyan A, Isaacs A, Lee R et al (2015) Long term safety of sacral nerve modulation in Medicare beneficiaries. Neurourol Urodyn 34:659–663CrossRefPubMed
94.
Peters KM, Shen L, Mcguire M (2013) Effect of sacral neuromodulation rate on overactive bladder symptoms: a randomized crossover feasibility study. Low Urin Tract Symptoms 5:129–133CrossRefPubMed
Metadata
Title
Role of sacral neuromodulation in modern urogynaecology practice: a review of recent literature
Author
Samina Tahseen
Publication date
01-08-2018
Publisher
Springer London
Published in
International Urogynecology Journal / Issue 8/2018
Print ISSN: 0937-3462
Electronic ISSN: 1433-3023
DOI
https://doi.org/10.1007/s00192-017-3546-6

Other articles of this Issue 8/2018

International Urogynecology Journal 8/2018 Go to the issue

Original Article

Current practice patterns and knowledge among gynecologic surgeons of InterStim® programming after implantation

Original Article

Detrusor underactivity in pelvic organ prolapse

Original Article

Pre-operative guided imagery in female pelvic medicine and reconstructive surgery: a randomized trial

Letter to the Editor

Mechanical support of cardinal/uterosacral ligaments improves OAB symptoms: implications for management

Editorial

Quo vadis, vaginal mesh in pelvic organ prolapse?

Original Article

Discontinuation rate and adverse events after 1 year of vaginal pessary use in women with pelvic organ prolapse